COLOMBO NICOLETTA

Valenza, C., Nicolò, E., Mongillo, M., Trapani, D., Katrini, J., Boldrini, L., et al. (2025). Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study. THE ONCOLOGIST, 30(7 (July 2025)) [10.1093/oncolo/oyae330]. Detail

Harano, K., Fossati, R., Pardo, B., Galli, F., Hudson, E., Antill, Y., et al. (2025). Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma: the Asian cohort of the AtTEnd/ENGOT-EN7 trial. JOURNAL OF GYNECOLOGIC ONCOLOGY, 36(4) [10.3802/jgo.2025.36.e117]. Detail

Kim, Y., Nishio, S., Kim, S., Hasegawa, K., Dubot, C., Valeria Cáceres, M., et al. (2025). Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis. JOURNAL OF GYNECOLOGIC ONCOLOGY, 36(4) [10.3802/jgo.2025.36.e110]. Detail

Liu, J., Colombo, N., Oza, A., Frenel, J., Corr, B., Rubinstein, M., et al. (2025). ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma. JOURNAL OF CLINICAL ONCOLOGY, 43(26), 2897-2907 [10.1200/JCO-24-01606]. Detail

Randall, L., Xiang, Y., Matsumoto, T., Giannarelli, D., Milla, D., Lopez, K., et al. (2025). Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer. GYNECOLOGIC ONCOLOGY, 199, 88-95 [10.1016/j.ygyno.2025.06.003]. Detail